Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention
- PMID: 19812222
- PMCID: PMC2777483
- DOI: 10.3945/jn.109.113332
Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention
Abstract
The reversible acetylation of histones is an important mechanism of gene regulation. During prostate cancer progression, specific modifications in acetylation patterns on histones are apparent. Targeting the epigenome, including the use of histone deacetylase (HDAC) inhibitors, is a novel strategy for cancer chemoprevention. Recently, drugs classified as HDAC inhibitors have shown promise in cancer clinical trials. We have previously found that sulforaphane (SFN), a compound found in cruciferous vegetables, inhibits HDAC activity in human colorectal and prostate cancer cells. Based on the similarity of SFN metabolites and other phytochemicals to known HDAC inhibitors, we previously demonstrated that sulforaphane acted as an HDAC inhibitor in the prostate, causing enhanced histone acetylation, derepression of P21 and Bax, and induction of cell cycle arrest/apoptosis, leading to cancer prevention. The ability of SFN to target aberrant acetylation patterns, in addition to effects on phase 2 enzymes, may make it an effective chemoprevention agent. These studies are important because of the potential to qualify or change recommendations for high-risk prostate cancer patients and thereby increase their survival through simple dietary choices incorporating easily accessible foods into their diets. These studies also will provide a strong scientific foundation for future large-scale human clinical intervention studies.
Figures
Similar articles
-
Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.Mol Nutr Food Res. 2011 Jul;55(7):999-1009. doi: 10.1002/mnfr.201000547. Epub 2011 Mar 4. Mol Nutr Food Res. 2011. PMID: 21374800 Free PMC article.
-
A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.Cancer Res. 2004 Aug 15;64(16):5767-74. doi: 10.1158/0008-5472.CAN-04-1326. Cancer Res. 2004. PMID: 15313918
-
Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition.Antioxid Redox Signal. 2015 Jun 1;22(16):1382-424. doi: 10.1089/ars.2014.6097. Epub 2014 Dec 19. Antioxid Redox Signal. 2015. PMID: 25364882 Free PMC article. Review.
-
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.Carcinogenesis. 2006 Apr;27(4):811-9. doi: 10.1093/carcin/bgi265. Epub 2005 Nov 9. Carcinogenesis. 2006. PMID: 16280330 Free PMC article.
-
Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds.Environ Mol Mutagen. 2009 Apr;50(3):213-21. doi: 10.1002/em.20454. Environ Mol Mutagen. 2009. PMID: 19197985 Free PMC article. Review.
Cited by
-
Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications.J Diabetes Res. 2015;2015:436879. doi: 10.1155/2015/436879. Epub 2015 May 28. J Diabetes Res. 2015. PMID: 26106624 Free PMC article. Review.
-
Promoter de-methylation of cyclin D2 by sulforaphane in prostate cancer cells.Clin Epigenetics. 2011;3(1):3. doi: 10.1186/1868-7083-3-3. Epub 2011 Oct 26. Clin Epigenetics. 2011. PMID: 22303414 Free PMC article.
-
Repression of transposable elements by histone biotinylation.J Nutr. 2009 Dec;139(12):2389-92. doi: 10.3945/jn.109.111856. Epub 2009 Oct 7. J Nutr. 2009. PMID: 19812216 Free PMC article.
-
Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):675-702. doi: 10.1007/s00210-023-02674-4. Epub 2023 Aug 24. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37615708 Review.
-
Correction to: In Vitro-In Vivo Dose Response of Ursolic Acid, Sulforaphane, PEITC, and Curcumin in Cancer Prevention.AAPS J. 2018 Feb 6;20(2):27. doi: 10.1208/s12248-018-0190-0. AAPS J. 2018. PMID: 29411155
References
-
- Brinkmann H, Dahler AL, Popa C, Serewko MM, Parsons PG, Gabrielli BG, Burgess AJ, Saunders NA. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem. 2001;276:22491–9. - PubMed
-
- Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun. 2001;287:705–13. - PubMed
-
- Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004;59:177–89. - PubMed
-
- Halkidou K, Cook S, Leung HY, Neal DE, Robson CN. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol. 2004;45:382–9, author reply 9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
